hbx

HBX is a deubiquitinase inhibitor. It inhibits HAdV type 5 (species C, HAdV-C5) replication and oncogenic transformation through inhibition of the cellular pro-viral factor ubiquitin-specific protease 7 (USP7). HBX also significantly inhibits virus genome replication and progeny release of all adenovirus types tested, with the exception of types 12 and 31, from tested species.

IR415 选择性地与 HBx 相互作用 (Kd=2 nM) 并阻断 HBV 介导的 RNAi 抑制，逆转 HBx 蛋白对 Dicer 核糖核酸内切酶活性的抑制作用。IR415 具有抗 HBV 的活性。

HBX 19818 是一种特异性泛素特异性蛋白酶 7 (USP7) 抑制剂，IC50值为 28.1 μM。

HBX28258 is a recombinant human USP7 protein inhibitor. In human colon cancer and embryonic kidney cell, it acts by binding the active site through a covalent mechanism and selectively inactivating USP7 protein.

HBX 41108 (HBX-41108) 是一种泛素特异性蛋白酶 7 的非竞争性抑制剂，IC50为 424 nM。它诱导 p53 依赖的凋亡，抑制 USP7 介导的 p53 去泛素化以稳定 p53 并抑制癌细胞生长。

DL-Acetylshikonin can effectively inhibit tumor cells, it can be used to treat hepatocellular carcinoma cells expressing hepatitis B virus X protein (HBX) by inducing ER stress , an oncoprotein from hepatitis B virus. Acetylshikonin inhibits the production of eicosanoid, is due to the attenuation of cytosolic phospholipase A(2) membrane recruitment via the decrease in [Ca(2+)](i) and to the blockade of cyclooxygenase and 5-lipoxygenase activity.